Opportunity Information: Apply for HRSA 09 139
Apply for HRSA 09 139
- The Health Resources and Services Administration in the health sector is offering a public funding opportunity titled "Genetic Services Grants to Support Comprehensive Medical Care for Cooleys Anemia/Thalassemia" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.110 Maternal and Child Health Federal Consolidated Programs.
- This funding opportunity was created on Oct 3, 2008 and posted on Oct 3, 2008.
- Applicants must submit their applications by Dec 3, 2008. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $520,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $173,000.00 in funding.
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- As cited in 42 CFR part 51a.3 (a), any public or private entity, including an Indian tribe or tribal organization (as those terms are defined at 25 U.S.C. 450b), and a faith based and community based organization, is eligible to apply for this Federal funding. Applicants must demonstrate no less than 5 years of cummulative experience in providing a system of comprehensive care and medical management for individuals and families at risk for or affected by Cooleys Anemia/Thalassemia.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Health Resources and Services Administration (HRSA) announced a discretionary grant opportunity titled "Genetic Services - Grants to Support Comprehensive Medical Care for Cooleys Anemia/Thalassemia" (Funding Opportunity Number HRSA-09-139). The program was designed to fund up to three demonstration projects that would showcase an effective, replicable model for delivering comprehensive care and long-term medical management for people who have thalassemia, as well as individuals and families who are at risk. The emphasis is on building or strengthening an organized system of care rather than supporting isolated clinical services, with the goal of improving outcomes for a population that often requires lifelong, highly coordinated treatment.
At the center of the opportunity is the expectation that applicants will operate a broad, integrated network of services. HRSA described this model as spanning the full continuum: screening and early identification, diagnostic evaluation, genetic and family counseling, patient and family education, and psychosocial supports, alongside specialized medical care. Because severe thalassemia commonly requires frequent red blood cell transfusions, the model also needed to include transfusion management as a routine service. A major clinical priority highlighted in the announcement is iron overload, a serious complication that can result from repeated transfusions. Projects were therefore expected to demonstrate strong systems for monitoring iron burden and providing prevention and treatment services (including clinical follow-up and care coordination) to reduce long-term organ damage and other complications.
The clinical focus reflects the nature of thalassemia as a group of inherited blood disorders, with particular attention to the most severe forms, Beta Thalassemia Major and Alpha Thalassemia Major. The announcement noted that alpha and beta thalassemia occur predominantly among individuals of African, Asian, Mediterranean, and Middle Eastern descent. In practice, that framing signals that strong projects would be prepared to deliver culturally and linguistically appropriate services, and to connect effectively with communities that are more likely to be affected, especially in areas where these populations are concentrated.
Funding details were straightforward and relatively fixed. HRSA anticipated making three awards with an estimated total program funding of $520,000. Each award was set at $173,000 (both the ceiling and the floor were listed as $173,000), and there was no cost-sharing or matching requirement. The Catalog of Federal Domestic Assistance (CFDA) number associated with the opportunity was 93.110, under the Maternal and Child Health Federal Consolidated Programs.
Eligibility was broad in terms of organizational type, but strict in terms of experience. Under 42 CFR part 51a.3(a), any public or private entity could apply, including Indian tribes and tribal organizations (as defined at 25 U.S.C. 450b), as well as faith-based and community-based organizations. However, applicants had to demonstrate at least five years of cumulative experience providing a system of comprehensive care and medical management for individuals and families at risk for or affected by Cooleys anemia/thalassemia. This requirement indicates HRSA was looking for established programs with demonstrated capacity to coordinate complex, multi-service care over time, rather than new start-ups.
Key dates show that this was a time-limited, archived opportunity. The announcement was posted on October 3, 2008, and the application deadline was December 3, 2008 (original and current closing dates matched). The opportunity was later archived on March 27, 2009. For access issues and applicant support at the time, HRSA directed people to the HRSA Call Center (CallCenter@HRSA.GOV) and provided phone contact options (877-464-4772 and 301-998-7373).
Frequently Asked Questions (FAQs)
1. What is the name of this HRSA grant opportunity?
The opportunity is titled "Genetic Services - Grants to Support Comprehensive Medical Care for Cooleys Anemia/Thalassemia."
2. What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is HRSA-09-139.
3. What is the overall purpose of this grant program?
The purpose is to fund demonstration projects that show an effective, replicable model for delivering comprehensive care and long-term medical management for people with thalassemia, as well as for individuals and families who are at risk.
4. How many awards did HRSA plan to make?
HRSA anticipated making up to three awards.
5. What was the estimated total funding available under this opportunity?
The estimated total program funding was $520,000.
6. How much funding was available per award?
Each award was set at $173,000. The ceiling and the floor were both listed as $173,000.
7. Was cost sharing or matching required?
No. There was no cost-sharing or matching requirement stated for this opportunity.
8. What kind of projects was HRSA trying to fund?
HRSA was seeking demonstration projects that strengthen or build an organized, integrated system of care for thalassemia across the full continuum of services, rather than projects that mainly fund isolated clinical services.
9. What does HRSA mean by an "organized system of care" in this announcement?
Based on the announcement, HRSA expected a broad, integrated network of services spanning screening and early identification, diagnostic evaluation, genetic and family counseling, patient and family education, psychosocial supports, and specialized medical care, delivered in a coordinated way to support long-term management.
10. What services were expected to be included in the model of care?
The model described by HRSA included screening and early identification, diagnostic evaluation, genetic and family counseling, patient and family education, psychosocial supports, and specialized medical care as part of a coordinated continuum.
11. Was transfusion management expected to be part of the project?
Yes. Because severe thalassemia often requires frequent red blood cell transfusions, transfusion management was expected to be included as a routine service within the care model.
12. Why did HRSA emphasize iron overload in this opportunity?
The announcement highlighted iron overload as a serious complication of repeated transfusions. Projects were expected to demonstrate strong systems for monitoring iron burden and providing prevention and treatment services, including clinical follow-up and care coordination, to reduce long-term organ damage and other complications.
13. What clinical forms of thalassemia were specifically highlighted?
The announcement drew particular attention to the most severe forms: Beta Thalassemia Major and Alpha Thalassemia Major.
14. Who was the intended population served by these demonstration projects?
The intended population included people who have thalassemia and individuals and families who are at risk, with an emphasis on long-term, highly coordinated treatment needs.
15. Did HRSA identify any populations more commonly affected by alpha and beta thalassemia?
Yes. The announcement stated that alpha and beta thalassemia occur predominantly among individuals of African, Asian, Mediterranean, and Middle Eastern descent.
16. Was there an expectation about cultural or linguistic appropriateness of services?
While the announcement did not list specific language requirements, it framed the epidemiology of thalassemia in a way that signals strong projects should be prepared to deliver culturally and linguistically appropriate services and connect effectively with communities more likely to be affected.
17. What types of organizations were eligible to apply?
Eligibility was broad: any public or private entity could apply, including Indian tribes and tribal organizations (as defined at 25 U.S.C. 450b), as well as faith-based and community-based organizations.
18. Were there any experience requirements for applicants?
Yes. Applicants had to demonstrate at least five years of cumulative experience providing a system of comprehensive care and medical management for individuals and families at risk for or affected by Cooleys anemia/thalassemia.
19. What does the five-year experience requirement suggest about the types of applicants HRSA wanted?
It indicates HRSA was looking for established programs with demonstrated capacity to coordinate complex, multi-service care over time, rather than new start-ups.
20. What is the CFDA number associated with this opportunity?
The CFDA number associated with the opportunity was 93.110, under the Maternal and Child Health Federal Consolidated Programs.
21. When was the opportunity posted?
The announcement was posted on October 3, 2008.
22. What was the application deadline?
The application deadline was December 3, 2008. The original and current closing dates matched.
23. Is this opportunity still open?
No. The opportunity was time-limited and later archived on March 27, 2009.
24. Who was listed as a point of contact for access issues or applicant support?
HRSA directed applicants to the HRSA Call Center at CallCenter@HRSA.GOV. Phone contacts were 877-464-4772 and 301-998-7373.
25. What is meant by "demonstration project" in the context of this announcement?
In this context, a demonstration project is one intended to showcase an effective, replicable approach for comprehensive thalassemia care and long-term medical management, with an emphasis on coordinated systems rather than stand-alone services.
Browse more opportunities from the same category: Health
Next opportunity: Strategic Agricultural Initiative FY09 Request for Applications
Previous opportunity: Enhancing Access to Quality HIV Care for Women of Color 1) Demonstrations Sites and 2) Evaluation and Technical Assisance Center
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HRSA 09 139
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (HRSA 09 139) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploratory and Developmental Grant to Improve Health Care Quality through Health Information Technology (IT) (R21) Apply for PAR 08 269 Funding Number: PAR 08 269 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $200,000 |
| Utilizing Health Information Technology (IT) to Improve Health Care Quality (R18) Apply for PAR 08 270 Funding Number: PAR 08 270 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Small Research Grant to Improve Health Care Quality through Health Information Technology (IT) (R03) Apply for PAR 08 268 Funding Number: PAR 08 268 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Ancillary Studies in Clinical Trials (R01) Apply for RFA HL 09 001 Funding Number: RFA HL 09 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Basic HIV Vaccine Discovery Research (R01) Apply for RFA AI 08 053 Funding Number: RFA AI 08 053 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Roadmap Transformative R01 Program (R01) Apply for RFA RM 08 029 Funding Number: RFA RM 08 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Short Courses on Mathematical, Statistical, and Computational Tools for Studying Biological Systems (R25) Apply for PA 09 002 Funding Number: PA 09 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Building Interdisciplinary Research Team (BIRT) Revision Awards (R01) Apply for RFA AR 09 001 Funding Number: RFA AR 09 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Airway Smooth Muscle Function and Targeted Therapeutics in Human Asthma (R01) Apply for RFA HL 09 007 Funding Number: RFA HL 09 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Approaches to Target Identification and Assay Development for Fungal Diagnosis (R21/R33) Apply for RFA AI 08 055 Funding Number: RFA AI 08 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neurodevelopment and Neuroendocrine Signaling in Adolescence Relevance to Mental Health (R01) Apply for PA 09 008 Funding Number: PA 09 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neurodevelopment and Neuroendocrine Signaling in Adolescence Relevance to Mental Health (R21) Apply for PA 09 009 Funding Number: PA 09 009 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Circadian Coupled Cellular Function in Heart, Lung, and Blood Tissue (R01) Apply for RFA HL 09 012 Funding Number: RFA HL 09 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Dental Public Health Residency Training Grants Apply for HRSA 09 200 Funding Number: HRSA 09 200 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Training and Technical Assistance Cooperative Agreements (NCA) Apply for HRSA 09 193 Funding Number: HRSA 09 193 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Basic/Core Area Health Education Centers Apply for HRSA 09 123 Funding Number: HRSA 09 123 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Model State Supported Area Health Education Centers Apply for HRSA 09 124 Funding Number: HRSA 09 124 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Public Education Efforts to Increase Solid Organ Donation Apply for HRSA 09 185 Funding Number: HRSA 09 185 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Fine Mapping and Function of Genes for Type 1 Diabetes (DP3) Apply for RFA DK 08 006 Funding Number: RFA DK 08 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Characterizing the Blood Stem Cell Niche (R01) Apply for RFA HL 09 010 Funding Number: RFA HL 09 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HRSA 09 139", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.